Greenwich Lifesciences Stock Fundamentals
| GLSI Stock | USD 13.40 0.19 1.44% |
Greenwich Lifesciences fundamentals help investors to digest information that contributes to Greenwich Lifesciences' financial success or failures. It also enables traders to predict the movement of Greenwich Stock. The fundamental analysis module provides a way to measure Greenwich Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Greenwich Lifesciences stock.
As of now, Greenwich Lifesciences' Interest Income is increasing as compared to previous years. Greenwich | Select Account or Indicator |
Greenwich Lifesciences Company Current Valuation Analysis
Greenwich Lifesciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Greenwich Lifesciences Current Valuation | 169.4 M |
Most of Greenwich Lifesciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Greenwich Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Greenwich Current Valuation Historical Pattern
Today, most investors in Greenwich Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Greenwich Lifesciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Greenwich Lifesciences current valuation as a starting point in their analysis.
Greenwich Lifesciences Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Greenwich Lifesciences has a Current Valuation of 169.4 M. This is 98.82% lower than that of the Biotechnology sector and 96.35% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.98% higher than that of the company.
Greenwich Lifesciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Greenwich Lifesciences's current stock value. Our valuation model uses many indicators to compare Greenwich Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Greenwich Lifesciences competition to find correlations between indicators driving Greenwich Lifesciences's intrinsic value. More Info.Greenwich Lifesciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Greenwich Lifesciences' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Greenwich Lifesciences' earnings, one of the primary drivers of an investment's value.Greenwich Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Greenwich Lifesciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Greenwich Lifesciences could also be used in its relative valuation, which is a method of valuing Greenwich Lifesciences by comparing valuation metrics of similar companies.Greenwich Lifesciences is currently under evaluation in current valuation category among its peers.
Greenwich Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Greenwich Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Greenwich Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Greenwich Fundamentals
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 169.4 M | ||||
| Shares Outstanding | 13.14 M | ||||
| Shares Owned By Insiders | 52.92 % | ||||
| Shares Owned By Institutions | 8.69 % | ||||
| Number Of Shares Shorted | 490.37 K | ||||
| Price To Book | 35.17 X | ||||
| EBITDA | (9.32 M) | ||||
| Net Income | (8.89 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 294.41 K | ||||
| Current Ratio | 65.74 X | ||||
| Book Value Per Share | 0.52 X | ||||
| Cash Flow From Operations | (6.48 M) | ||||
| Short Ratio | 21.41 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 38.0 | ||||
| Beta | 3.32 | ||||
| Market Capitalization | 175.22 M | ||||
| Total Asset | 6.99 M | ||||
| Retained Earnings | (50.36 M) | ||||
| Working Capital | 6.7 M | ||||
| Net Asset | 6.99 M |
About Greenwich Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Greenwich Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Greenwich Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Greenwich Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | (316.42) | (332.24) | |
| Cost Of Revenue | 4.2 K | 4 K |
Currently Active Assets on Macroaxis
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:Check out Greenwich Lifesciences Piotroski F Score and Greenwich Lifesciences Altman Z Score analysis. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Return On Assets (0.72) | Return On Equity (1.24) |
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.